{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:38:27Z","timestamp":1791563907372,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jns.2024.122989","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:24:05Z","timestamp":1712190245000},"page":"122989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Trends from two decades of orphan designations in paediatric rare neuromuscular diseases"],"prefix":"10.1016","volume":"460","author":[{"given":"Dinah M.","family":"Duarte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Beatriz","family":"da Silva Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sepodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.122989_bb0005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database","volume":"28","author":"Nguengang Wakap","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.jns.2024.122989_bb0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/d41573-019-00180-y","article-title":"How many rare diseases are there?","volume":"19","author":"Haendel","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jns.2024.122989_bb0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13023-022-02299-5","article-title":"The national economic burden of rare disease in the United States in 2019","volume":"17","author":"Yang","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jns.2024.122989_bb0020","series-title":"The Building Blocks to Make Rare Disease Treatments more Common","author":"Willmer","year":"2022"},{"key":"10.1016\/j.jns.2024.122989_bb0025","author":"European Medicines Agency"},{"key":"10.1016\/j.jns.2024.122989_bb0030","first-page":"8","article-title":"New therapeutics options for pediatric neuromuscular disorders","author":"Flotats-Bastardas","year":"2020","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.jns.2024.122989_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2023.08.034","article-title":"Pediatric neuromuscular diseases","volume":"149","author":"Rathore","year":"2023","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.jns.2024.122989_bb0040","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajmg.a.38418","article-title":"Treating pediatric neuromuscular disorders: the future is now","volume":"176","author":"Dowling","year":"2018","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.jns.2024.122989_bb0045","series-title":"Regulation (EC) No 141\/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products","volume":"vol. L 18","author":"European Commission","year":"2000"},{"key":"10.1016\/j.jns.2024.122989_bb0050","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.drudis.2017.06.003","article-title":"Establishing rarity in the context of orphan medicinal product designation in the European Union","volume":"23","author":"Tsigkos","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jns.2024.122989_bb0055","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.drudis.2017.10.012","article-title":"Marketing authorisation of orphan medicines in Europe from 2000 to 2013","volume":"23","author":"Hofer","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jns.2024.122989_bb0060","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drudis.2017.09.015","article-title":"Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditions","volume":"23","author":"Sheean","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jns.2024.122989_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/d41573-019-00199-1","article-title":"A decade of optimizing drug development for rare neuromuscular disorders through TACT","volume":"19","author":"Wagner","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jns.2024.122989_bb0070","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13023-021-01901-6","article-title":"Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases","volume":"16","author":"Miller","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jns.2024.122989_bb0075","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nrg3555","article-title":"Rare-disease genetics in the era of next-generation sequencing: discovery to translation","volume":"14","author":"Boycott","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jns.2024.122989_bb0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13023-023-02790-7","article-title":"A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act","volume":"18","author":"Fermaglich","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jns.2024.122989_bb0085","first-page":"1","article-title":"Translational medicine in neuromuscular disorders: from academia to industry","volume":"13","author":"Cowling","year":"2020","journal-title":"DMM Dis. Model Mech."},{"key":"10.1016\/j.jns.2024.122989_bb0090","series-title":"Understanding Neuromuscular Disease Care","author":"Aitken","year":"2018"},{"key":"10.1016\/j.jns.2024.122989_bb0095","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13023-018-0930-3","article-title":"Investigating the landscape of US orphan product approvals","volume":"13","author":"Miller","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jns.2024.122989_bb0100","author":"US Food and Drug Administration Center for Drug Evaluation, Research"},{"key":"10.1016\/j.jns.2024.122989_bb0105","author":"US Food and Drug Administration Center for Biologics, Research"},{"key":"10.1016\/j.jns.2024.122989_bb0110","series-title":"Annual Report on the Use of the Special Contribution for Orphan Medicinal Products \u2013 2019","first-page":"1","volume":"vol. 31","author":"European Medicines Agency","year":"2020"},{"key":"10.1016\/j.jns.2024.122989_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2020.104810","article-title":"The translational value of animal models in orphan medicines designations for rare paediatric neurological diseases","volume":"118","author":"Duarte","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.jns.2024.122989_bb0120","first-page":"13","article-title":"Moving neuromuscular disorders research forward: from novel models to clinical studies","author":"van Putten","year":"2020","journal-title":"DMM Dis. Model. Mech."},{"key":"10.1016\/j.jns.2024.122989_bb0125","first-page":"60","article-title":"Overcoming gaps in the treatment of neurodegenerative disease","author":"Alzheimer","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jns.2024.122989_bb0130","author":"European Commission"},{"key":"10.1016\/j.jns.2024.122989_bb0135","article-title":"European medicines agency rare disease (orphan) designations","author":"European Medicines Agency","year":"2023","journal-title":"EMA Excel Table All Orphan Des."},{"key":"10.1016\/j.jns.2024.122989_bb0140","first-page":"2019","article-title":"International classification of diseases for mortality and morbidity statistics (11th revision)","volume":"11","author":"World Health Organization","year":"2018","journal-title":"World Heal Organ."},{"key":"10.1016\/j.jns.2024.122989_bb0145","unstructured":"Orphanet. Orphanet Catalogues Rare Diseases Database n.d. https:\/\/www.orpha.net\/consor\/cgi-bin\/Disease.php?lng=EN (accessed February 23, 2023)."},{"key":"10.1016\/j.jns.2024.122989_bb0150","unstructured":"European Union. EU Clinical Trials Register. EudraCT database n.d. https:\/\/www.clinicaltrialsregister.eu\/ (accessed February 23, 2023)."},{"key":"10.1016\/j.jns.2024.122989_bb0155","unstructured":"National Library of Medicine. US Clinical Trials Register. ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ (accessed February 23, 2023)."},{"key":"10.1016\/j.jns.2024.122989_bb0160","author":"European Medicines Agency"},{"key":"10.1016\/j.jns.2024.122989_bb0165","author":"European Medicines Agency"},{"key":"10.1016\/j.jns.2024.122989_bb0170","author":"European Medicines Agency"},{"key":"10.1016\/j.jns.2024.122989_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.759994","article-title":"Lessons learned from translational research in neuromuscular diseases: impact on study design, outcome measures and managing expectation","volume":"12","author":"Stimpson","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.jns.2024.122989_bb0180","article-title":"Improving the utility and translation of animal models for nervous system disorders","author":"Pankevich","year":"2013","journal-title":"Improv. Util. Transl. Anim. Model. Nerv. Syst. Disord."},{"key":"10.1016\/j.jns.2024.122989_bb0185","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41573-019-0049-9","article-title":"Therapies for rare diseases: therapeutic modalities, progress and challenges ahead","volume":"19","author":"Tambuyzer","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jns.2024.122989_bb0190","first-page":"15","article-title":"The orphan drug pipeline in Europe","author":"Morel","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jns.2024.122989_bb0195","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nrd.2016.80","article-title":"Worldwide collaboration for orphan drug designation","volume":"15","author":"Mariz","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jns.2024.122989_bb0200","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-017-0578-4","article-title":"Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012","volume":"12","author":"Pauwels","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jns.2024.122989_bb0205","first-page":"5","article-title":"Rare diseases, orphan medicines: getting the facts straight","volume":"44","author":"European Medicines Agency","year":"2018","journal-title":"Eur. Med. Agency"},{"key":"10.1016\/j.jns.2024.122989_bb0210","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.2147\/IJN.S106625","article-title":"Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside","volume":"11","author":"Zatsepin","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jns.2024.122989_bb0215","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/wrna.1158","article-title":"Targeting RNA splicing for disease therapy","volume":"4","author":"Havens","year":"2013","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"10.1016\/j.jns.2024.122989_bb0220","series-title":"Committee for Medicinal Products for Human Use (CHMP) Minutes for the Meeting March 2023","volume":"44","author":"European Medicines Agency","year":"2023"},{"key":"10.1016\/j.jns.2024.122989_bb0225","series-title":"Committee for Medicinal Products for Human Use (CHMP) Minutes for the Meeting April 2023","volume":"vol. 44","author":"European Medicines Agency","year":"2023"},{"key":"10.1016\/j.jns.2024.122989_bb0230","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10928-019-09645-4","article-title":"FDA\u2019s Office of Orphan Products Development: providing incentives to promote the development of products for rare diseases","volume":"46","author":"Patel","year":"2019","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.jns.2024.122989_bb0235","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J. Health Econ."},{"key":"10.1016\/j.jns.2024.122989_bb0240","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/d41573-022-00019-z","article-title":"Research on rare diseases: ten years of progress and challenges at IRDiRC","volume":"21","author":"Monaco","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jns.2024.122989_bb0245","author":"European Medicines Agency"},{"key":"10.1016\/j.jns.2024.122989_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2021.809035","article-title":"Orphan medicinal products for the treatment of pancreatic cancer: lessons learned from two decades of orphan designation","volume":"11","author":"Mulder","year":"2021","journal-title":"Front. Oncol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24001242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24001242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T23:46:25Z","timestamp":1716335185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24001242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":50,"alternative-id":["S0022510X24001242"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.122989","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends from two decades of orphan designations in paediatric rare neuromuscular diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.122989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122989"}}